Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication
Yaws
About this trial
This is an interventional treatment trial for Yaws focused on measuring Azithromycin, Endemic treponematoses, Mass drug administration, Eradication, Papua New Guinea
Eligibility Criteria
Inclusion Criteria:
- all people resident or not in wards in the study region present at time of implementation or in subsequent surveys
Exclusion Criteria:
- Children younger than 6 months
- Known allergy to macrolide antibiotics
- Refusal at village or individual levels
Sites / Locations
- Namatanai Rural Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Intervention
Control
Repeated total community treatment, TCT with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single dose every 6 months, for 12 months (3 doses). Study interventions are: R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin.
Single total community treatment, TCT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at month 0 (1 dose); followed by two total targeted treatment, TTT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at months 6 and 12. Study interventions are: R1-Total community treatment with azithromycin, R2-Total targeted treatment with azithromycin, R3-Total targeted treatment with azithromycin.